Novo Nordisk’s Shares Take a Hit

Novo Nordisk’s stock price has taken a nosedive after the company predicted sales declines for this year. It’s not exactly the news investors wanted to hear.

A Plan to Recover

The company’s counting on its Wegovy pill and a new weight loss injectable, CagriSema, to win back market share in the U.S. It’s a tough road ahead, but they’re betting big on these two products. Let’s see if it pays off.